Background A safe and efficacious vaccine against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of …

Background Older adults (aged ≥70 years) are at increased risk of severe disease and
death if they develop COVID-19 and are therefore a priority for immunisation should an …

Background Assessment of the safety and efficacy of vaccines against the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is …

Background Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40
million people globally living with HIV who might have less functional immunity and more …

Background People living with HIV are at an increased risk of fatal outcome when admitted
to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to …

Background Assessing safety and efficacy of Covid-19 vaccines in different populations is
essential, as is investigation of efficacy against emerging SARS-CoV-2 variants of concern …

… Ramasamy, 5 Sarah Rhead, 5 Hannah Robinson, 5 Nicola Robinson, 1, 10 Helen
Sanders, 2 Sonia Serrano, 7 Tom Tipton, 9 Anele Waters, 8 Panagiota Zacharopoulou, 1 …

Background Vaccination of children and young people against SARS-CoV-2 is recommended
in some countries. Scarce data have been published on immune responses induced by …

Background COVID-19 vaccine rollout is lagging in Africa, where there has been a high rate
of SARS-CoV-2 infection. We aimed to evaluate the effect of SARS-CoV-2 infection before …

COVID-19 vaccine efficacy (VE) has been observed to vary against antigenically distinct
SARS-CoV-2 variants of concern (VoC). Here we report the final analysis of VE and safety from …